Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
SGLT2 inhibitor100 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00001 | 35259705 | Diabetes Metab Syndr | Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis. | 2022 | Details |
| A00217 | 35181350 | Diabetes Res Clin Pract | Metabolic Changes Induced by Dapagliflozin, an SGLT2 Inhibitor, in Japanese Patients with Type 2 Diabetes Treated by Oral Anti-diabetic Agents: A Randomized, Clinical Trial. | 2022 | Details |
| A00249 | 35166009 | Diabetes Obes Metab | Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. | 2022 | Details |
| A00609 | 35030323 | Lancet Gastroenterol Hepatol | Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. | 2022 | Details |
| A01065 | 34882949 | Diabetes Obes Metab | Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database. | 2022 | Details |
| A01613 | 34680463 | Biomedicines | Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. | 2021 | Details |
| A01811 | 34606980 | Endocr Pract | Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. | 2021 | Details |
| A02363 | 34402473 | Eur J Gastroenterol Hepatol | Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression. | 2021 | Details |
| A02567 | 34326946 | World J Diabetes | Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. | 2021 | Details |
| A02827 | 34227216 | Diabetes Obes Metab | Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. | 2021 | Details |
| A02838 | 34224699 | Eur J Pharmacol | Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway. | 2021 | Details |
| A02848 | 34220701 | Front Endocrinol (Lausanne) | Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. | 2021 | Details |
| A02857 | 34214406 | Expert Opin Investig Drugs | Anti-diabetic drugs and NASH: from current options to promising perspectives. | 2021 | Details |
| A03370 | 34027265 | Hepatol Commun | Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus. | 2021 | Details |
| A03740 | 33882758 | Expert Rev Clin Pharmacol | Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. | 2021 | Details |
| A03753 | 33877366 | Diabetologia | Liver-targeting drugs and their effect on blood glucose and hepatic lipids. | 2021 | Details |
| A03789 | 33862461 | Biochem Biophys Res Commun | Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2. | 2021 | Details |
| A03850 | 33847462 | Hepatol Res | Meta-analysis of the effect of sodium-glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. | 2021 | Details |
| A03995 | 33798599 | Eur J Pharmacol | Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH. | 2021 | Details |
| A04359 | 33648515 | Cardiovasc Diabetol | Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. | 2021 | Details |
| A04362 | 33647823 | Int Immunopharmacol | The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway. | 2021 | Details |
| A04506 | 33594581 | Diabetes Ther | Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial. | 2021 | Details |
| A04700 | 33535836 | Expert Rev Clin Pharmacol | An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy. | 2021 | Details |
| A04739 | 33520110 | World J Diabetes | Novel glucose-lowering drugs for non-alcoholic fatty liver disease. | 2021 | Details |
| A04769 | 33511282 | Clin Exp Hepatol | SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review. | 2020 | Details |
| A04892 | 33464703 | Diabetes Obes Metab | Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial. | 2021 | Details |
| A04950 | 33439540 | J Gastroenterol Hepatol | The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease. | 2020 | Details |
| A05415 | 33268450 | BMJ Open Diabetes Res Care | SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews. | 2020 | Details |
| A06093 | 33010191 | Diabetes Metab Res Rev | Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials. | 2020 | Details |
| A06274 | 32945071 | Diabetes Obes Metab | A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer? | 2020 | Details |
| A06367 | 32912770 | Dig Liver Dis | Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. | 2020 | Details |
| A07241 | 32571083 | Ann Pharmacother | A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A07401 | 32514450 | JGH Open | Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes. | 2019 | Details |
| A07543 | 32448832 | Intern Med | SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology. | 2020 | Details |
| A07566 | 32440840 | J Nephrol | Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease. | 2020 | Details |
| A08140 | 32231437 | Diabetes Metab Syndr Obes | Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice. | 2020 | Details |
| A08288 | 32168769 | Int J Mol Sci | Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A08318 | 32153507 | Front Endocrinol (Lausanne) | Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. | 2020 | Details |
| A08503 | 32083798 | J Diabetes Investig | Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. | 2020 | Details |
| A08516 | 32077613 | Liver Int | A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. | 2020 | Details |
| A08701 | 32017891 | Am J Med | Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know? | 2020 | Details |
| A08737 | 32006266 | Adv Exp Med Biol | Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. | 2021 | Details |
| A08752 | 32000955 | J Am Coll Cardiol | Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. | 2020 | Details |
| A08871 | 31955626 | Endocr Res | Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice. | 2020 | Details |
| A09047 | 31889754 | J Clin Exp Hepatol | Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A09056 | 31888083 | Int J Mol Sci | Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules. | 2019 | Details |
| A09120 | 31867105 | Cancer Metab | SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia. | 2019 | Details |
| A09349 | 31782258 | Physiol Rep | SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model. | 2019 | Details |
| A09381 | 31769484 | Clin Sci (Lond) | Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats. | 2019 | Details |
| A09583 | 31686884 | Diabetes Metab Syndr Obes | Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide. | 2019 | Details |
| A09671 | 31652578 | Int J Mol Sci | The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. | 2019 | Details |
| A09917 | 31561285 | FEBS Open Bio | Inhibition of sodium-glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis-related kidney disease. | 2019 | Details |
| A10076 | 31497874 | Br J Pharmacol | Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice. | 2019 | Details |
| A10307 | 31391764 | World J Gastroenterol | Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease. | 2019 | Details |
| A10769 | 31202833 | Metabolism | Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice. | 2019 | Details |
| A10989 | 31089576 | J Obes Metab Syndr | The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. | 2019 | Details |
| A11228 | 30984539 | FEBS Open Bio | Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH). | 2019 | Details |
| A11635 | 30810254 | Int J Clin Pract | Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. | 2019 | Details |
| A11852 | 30708071 | Diabetes Metab | Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. | 2019 | Details |
| A11911 | 30684076 | Dig Dis Sci | Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. | 2019 | Details |
| A12190 | 30568471 | Diabetes Metab Syndr Obes | Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis. | 2018 | Details |
| A12665 | 30338118 | Obes Sci Pract | Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study. | 2018 | Details |
| A13075 | 30149145 | Diabetes Metab | SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes. | 2018 | Details |
| A13117 | 30132035 | Diabetologia | SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. | 2018 | Details |
| A14053 | 29608898 | Eur J Pharmacol | Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation. | 2018 | Details |
| A14182 | 29547706 | Atherosclerosis | Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. | 2018 | Details |
| A14455 | 29402900 | Sci Rep | Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. | 2018 | Details |
| A14510 | 29376471 | Adipocyte | Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization. | 2018 | Details |
| A14771 | 29247356 | J Gastroenterol | Current and future pharmacological therapies for NAFLD/NASH. | 2017 | Details |
| A15414 | 28924123 | Intern Med | The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin. | 2017 | Details |
| A15703 | 28751548 | Diabetes Care | Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. | 2017 | Details |
| A15768 | 28719078 | Diabetes Obes Metab | Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. | 2017 | Details |
| A17943 | 27462372 | Diabetol Metab Syndr | Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. | 2016 | Details |
| A18736 | 26977813 | PLoS One | Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. | 2016 | Details |
| A19142 | 26731267 | PLoS One | The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. | 2016 | Details |
| A19328 | 26628836 | J Clin Exp Hepatol | Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. | 2015 | Details |
| A19388 | 26594248 | Diabetol Metab Syndr | Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. | 2015 | Details |
| A20839 | 25701721 | Eur J Pharmacol | Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. | 2015 | Details |
| A28641 | 35203369 | Cells | Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis. | 2022 | Details |
| A28693 | 35121372 | Biochem Biophys Res Commun | Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model. | 2022 | Details |
| A31276 | 30909602 | Cells | 2,4 Dinitrophenol as Medicine. | 2019 | Details |
| A32233 | 28912902 | Curr Ther Res Clin Exp | Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study. | 2017 | Details |
| A42421 | 34572340 | Biomedicines | Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes. | 2021 | Details |
| A42571 | 34142426 | Diabetes Obes Metab | Sodium-glucose cotransporter-2 inhibitors for type 2 diabetes mellitus in adults: An overview of 46 systematic reviews. | 2021 | Details |
| A43009 | 32821334 | World J Hepatol | Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling. | 2020 | Details |
| A43014 | 32812927 | Metabol Open | Treatment of nonalcoholic fatty liver disease with dapagliflozin in non-diabetic patients. | 2020 | Details |
| A43845 | 30706731 | Diab Vasc Dis Res | Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. | 2019 | Details |
| A47687 | 33682849 | Acta Biomed | PROS and CONS in general medicine and geriatrics, 2020. | 2021 | Details |
| A48751 | 29751356 | Clin Exp Pharmacol Physiol | Exploring novel pharmacotherapeutic applications and repurposing potential of sodium glucose CoTransporter 2 inhibitors. | 2018 | Details |
| A49718 | 35659603 | Clin Res Hepatol Gastroenterol | Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2022 | Details |
| A49820 | 35628485 | Int J Mol Sci | Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice. | 2022 | Details |
| A49867 | 35614469 | Cardiovasc Diabetol | The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. | 2022 | Details |
| A49962 | 35581956 | Hepatol Commun | Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study. | 2022 | Details |
| A50334 | 35430025 | J Clin Lipidol | JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. | 2022 | Details |
| A50386 | 35409028 | Int J Mol Sci | SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A50745 | 35280867 | Front Med (Lausanne) | Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. | 2022 | Details |
| A51328 | 35588918 | Pharmacol Res | The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications. | 2022 | Details |
| A51638 | 35421452 | Life Sci | Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review. | 2022 | Details |
| A52279 | 29371333 | Eur J Endocrinol | MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism? | 2018 | Details |
| A52310 | 28811292 | Am J Physiol Endocrinol Metab | Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. | 2017 | Details |